Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Novo Nordisk lifts guidance after first quarter beats expectations

Published 05/05/2021, 02:13 AM
Updated 05/05/2021, 04:45 AM
© Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo

By Nikolaj Skydsgaard

COPENHAGEN (Reuters) - Denmark's Novo Nordisk (NYSE:NVO) raised its sales and profit forecasts on Wednesday after beating first-quarter earnings expectations, lifting shares in the world's biggest maker of diabetes drugs.

Sales were still hit by the effect of patients and wholesalers stocking up on drugs last year in preparation for the COVID-19 pandemic, Novo said, but inventory changes and the timing of shipments had offset that in the first quarter.

"We are very encouraged with the sales growth in the first three months of 2021," Chief Executive Lars Fruergaard Jorgensen said.

Novo Nordisk now expects sales growth in local currencies this year to come in at between 6% and 10%, up from a previous forecast of 5% to 9%, and operating profit growth in local currencies in the range of 5% to 9%, up from an earlier estimate of 4% to 8%.

Shares in Novo Nordisk traded up 1.82% at 0753 GMT.

Sales in local currencies rose 7% in the first quarter to 33.8 billion Danish crowns ($5.46 billion), above a forecast of 32.5 billion in a Refinitiv poll, while operating profit came in at 14.98 billion Danish crowns, beating analysts' expectations for 14.6 billion.

"It's a strong start to the year," Sydbank analyst Soren Lontoft Hansen told Reuters.

By volume Novo Nordisk is the world's biggest insulin provider, but an increasingly competitive global insulin market means it aims to sell more of its newer drugs, many of which are used to treat type 2 diabetes.

Revenues were driven by a 13% rise in sales of its GLP-1 products, which imitate an intestinal hormone that stimulates insulin production, offsetting a 7% overall drop in insulin sales.

Sales of its recently launched once-daily diabetes pill Rybelsus grew 247% to 729 million crowns, which Hansen said lagged expectations as the pandemic had made it difficult for Novo to promote the drug to physicians.

© Reuters. FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016.  REUTERS/Guillaume Souvant/File Photo

"As the U.S. is gradually coming out of a lockdown... we are very optimistic that we'll stay on a very positive trajectory for Rybelsus," Chief Executive Jorgensen told a media briefing.

($1 = 6.1881 Danish crowns)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.